Vaishali Sanchorawala
Expertise in
18
conditions

Dr. Vaishali Sanchorawala

Hematology
Boston University Medical Center Radiologists Inc.
840 Harrison Ave, 
Boston, MA 
Expertise in
18
conditions
Boston University Medical Center Radiologists Inc.
840 Harrison Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vaishali Sanchorawala is a Hematologist in Boston, Massachusetts. Dr. Sanchorawala is highly rated in 18 conditions, according to our data. Her top areas of expertise are Primary Amyloidosis, Cardiac Amyloidosis, Multiple Myeloma, Bone Marrow Transplant, and Tissue Biopsy.

Her clinical research consists of co-authoring 223 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Boston Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Boston University Medical Center Radiologists Inc.
840 Harrison Ave, Boston, MA 02118
Other Locations
Boston Medical Center
1 Boston Medical Ctr Pl, Boston, MA 02118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drugs: Daratumumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Anti-thymocyte globulin, Cyclophosphamide, Filgrastim, Mycophenolate mofetil, Plerixafor
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Enrollment Status: Terminated
Publish Date: May 09, 2023
Intervention Type: Drug, Other
Study Drugs: Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 1
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
Enrollment Status: Terminated
Publish Date: March 28, 2022
Intervention Type: Drug
Study Drugs: Melphalan-Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 1
A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis
A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis
Enrollment Status: Completed
Publish Date: May 07, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

219 Total Publications

Optimized methods for efficient application of immunogold electron microscopy to amyloid fibrils typing.
Optimized methods for efficient application of immunogold electron microscopy to amyloid fibrils typing.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: November 23, 2025
Similar Doctors
Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology
Expertise in
11
conditions
Dr. Steven Dubois
Hematology | Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (1.8 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances

Steven Dubois is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Dubois is highly rated in 11 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma.

Expertise in
42
conditions
Dr. David Kuter
Hematology
Expertise in
42
conditions
Dr. David Kuter
Hematology

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (1.9 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kuter is a Hematologist in Boston, Massachusetts. Dr. Kuter is highly rated in 42 conditions, according to our data. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Autoimmune Hemolytic Anemia, and Splenectomy.

Expertise in
18
conditions
Dr. Raymond Comenzo
Hematology
Expertise in
18
conditions
Dr. Raymond Comenzo
Hematology

Tufts Medical Center Cancer Center

860 Washington St Bldg 8, 
Boston, MA 
 (1.3 miles away)
617-263-8312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Comenzo is a Hematologist in Boston, Massachusetts. Dr. Comenzo is highly rated in 18 conditions, according to our data. His top areas of expertise are Primary Amyloidosis, Multiple Myeloma, Cardiac Amyloidosis, Bone Marrow Transplant, and Tissue Biopsy. Dr. Comenzo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sanchorawala's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile